机器人解剖性肺切除项目启动期的作业成本分析
本研究回顾性比较2014年8月至2017年1月间接受VATS或RALS肺叶/肺段切除的患者,经1:1倾向性匹配后各74例。RALS组住院时间和胸管留置时间更短,总直接成本无显著差异,但总体可控成本显著低于VATS组。
要点
- RALS与VATS的30天死亡率无差异(0% vs 1.4%;P=1)。
- RALS组中位住院时间4天 vs 7天,胸管留置3天 vs 5天(P均<.001)。
- 总体中位可控成本RALS组显著低于VATS组($16,352 vs $21,154;P=.025)。
核心结论
- 在现有微创胸外科项目框架内可启动具有潜在成本优势的机器人辅助肺切除项目,且临床结果良好。
研究设计与样本
- 回顾性队列研究,2014年8月至2017年1月接受VATS或RALS肺叶/肺段切除的患者,经1:1倾向性匹配后RALS组74例、VATS组74例。
主要发现
- RALS组与VATS组30天死亡率无差异(0% vs 1.4%;P=1)。
- RALS组中位住院时间缩短(4天 vs 7天;P<.001),中位胸管留置时间缩短(3天 vs 5天;P<.001)。
- 总直接成本(含直接供应成本)两组无显著差异($6621 vs $6483;P=.784)。
- RALS组中位总手术成本和总单元支持成本更低,总体中位可控成本显著低于VATS组($16,352 vs $21,154;P=.025)。
临床怎么用
- RALS肺切除在项目启动期可维持与VATS相当的临床结果,并可能通过缩短住院时间降低总体可控成本。
局限性
- 回顾性研究,样本量有限(每组74例),成本分析基于单中心经验,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: While robotic-assisted lung resection has seen a significant rise in adoption, concerns remain regarding initial programmatic outcomes and potential increased costs. We present our initial outcomes and cost analysis since initiation of a robotic lung resection program. METHODS: Patients undergoing either video-assisted thoracoscopic lobectomy or segmentectomy (VATS) or robotic-assisted lobectomy or segmentectomy (RALS) between August of 2014 and January of 2017 underwent retrospective review. Patients underwent 1:1 propensity matching based on preoperative characteristics. Perioperative and 30-day outcomes were compared between groups. Detailed activity-based costing analysis was performed on individual patient encounters taking into effect direct and indirect controllable costs, including robotic operative supplies. RESULTS: There were no differences in 30-day mortality between RALS (n = 74) and VATS (n = 74) groups (0% vs 1.4%; P = 1). RALS patients had a decreased median length of stay (4 days vs 7 days; P < .001) and decreased median chest tube duration (3 days vs 5 days, P < .001). Total direct costs, including direct supply costs, were not significantly different between RALS and VATS ($6621 vs $6483; P = .784). Median total operating costs and total unit support costs, which are closely correlated to length of stay, were lower in the RALS group. Overall median controllable costs were significantly different between RALS and VATS ($16,352 vs $21,154; P = .025). CONCLUSIONS: A potentially cost-advantageous robotic-assisted pulmonary resection program can be initiated within the context of an existing minimally invasive thoracic surgery program while maintaining good clinical outcomes when compared with traditional VATS. Process-of-care changes associated with RALS may account for decreased costs in this setting.
引用
- Coyan GN, Lu M, Ruppert KM, et al. Activity-Based Cost Analysis of Robotic Anatomic Lung Resection During Program Implementation. Ann Thorac Surg. 2021. PMID: 33600792. doi:10.1016/j.athoracsur.2021.01.053
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。